WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317757
CAS#: 67392-87-4
Description: Drospirenone is a synthetic progestogen exhibiting antiandrogenic and antimineralocorticoid activity. This drug is used in oral contraceptives. Drospirenone binds to the progesterone receptor, the resulting complex becomes activated and binds to specific sites on DNA. This results in a suppression of LH activity and an inhibition of ovulation as well as an alteration in the cervical mucus and endometrium. This leads to an increased difficulty of sperm entry into the uterus and implantation.
Hodoodo Cat#: H317757
Name: Drospirenone
CAS#: 67392-87-4
Chemical Formula: C24H30O3
Exact Mass: 366.22
Molecular Weight: 366.501
Elemental Analysis: C, 78.65; H, 8.25; O, 13.10
Synonym: Drospirenone; dihydrospirorenone; drospirenone; ZK 3059; ZK30595;67392-87-4; Drospirenona; Drospirenonum; Dehydrospirorenone;
IUPAC/Chemical Name: (2'S,4aR,4bS,6aS,7aS,8aS,8bS,8cR,8dR,9aR)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7a,8,8a,8b,8c,8d,9,9a-tetradecahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-7,2'-furan]-2,5'(3H,4'H)-dione
InChi Key: METQSPRSQINEEU-DZJIEHTNSA-N
InChi Code: InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13?,14?,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
SMILES Code: O=C1CC[C@]2(C)[C@@]3([H])CC[C@@]([C@](OC4=O)(CC4)[C@]5([H])[C@@]6([H])C5)(C)[C@]6([H])[C@]3([H])C7C(C7)C2=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 366.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Borgo MV, Claudio ER, Silva FB, Romero WG, Gouvea SA, Moysés MR, Santos RL,
Almeida SA, Podratz PL, Graceli JB, Abreu GR. Hormonal therapy with estradiol and
drospirenone improves endothelium-dependent vasodilation in the coronary bed of
ovariectomized spontaneously hypertensive rats. Braz J Med Biol Res. 2016;49(1).
pii: S0100-879X2016000100601. doi: 10.1590/1414-431X20154655. Epub 2016 Nov 17.
PubMed PMID: 26577845; PubMed Central PMCID: PMC4678653.
2: Wang Q, Ma X, He J, Sun Q, Li Y, Li H. Binding properties of drospirenone with
human serum albumin and lysozyme in vitro. Spectrochim Acta A Mol Biomol
Spectrosc. 2016 Jan 15;153:612-8. doi: 10.1016/j.saa.2015.09.017. Epub 2015 Sep
30. PubMed PMID: 26448295.
3: Duijkers IJ, Heger-Mahn D, Drouin D, Colli E, Skouby S. Maintenance of
ovulation inhibition with a new progestogen-only pill containing drospirenone
after scheduled 24-h delays in pill intake. Contraception. 2015 Dec 16. pii:
S0010-7824(15)30022-6. doi: 10.1016/j.contraception.2015.12.007. [Epub ahead of
print] PubMed PMID: 26708301.
4: Wiesinger H, Berse M, Klein S, Gschwend S, Höchel J, Zollmann FS, Schütt B.
Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the
hormone drospirenone in combination with ethinylestradiol or estradiol. Br J Clin
Pharmacol. 2015 Dec;80(6):1399-410. doi: 10.1111/bcp.12745. Epub 2015 Oct 28.
PubMed PMID: 26271371.
5: de Nadai MN, Nobre F, Ferriani RA, Vieira CS. Effects of two contraceptives
containing drospirenone on blood pressure in normotensive women: a
randomized-controlled trial. Blood Press Monit. 2015 Dec;20(6):310-5. doi:
10.1097/MBP.0000000000000139. PubMed PMID: 26154851.
6: Bhattacharya SM, Jha A, DasMukhopadhyay L. Comparison of two contraceptive
pills containing drospirenone and 20μg or 30μg ethinyl estradiol for polycystic
ovary syndrome. Int J Gynaecol Obstet. 2015 Nov 6. pii: S0020-7292(15)00651-7.
doi: 10.1016/j.ijgo.2015.06.065. [Epub ahead of print] PubMed PMID: 26613823.
7: Giribela CR, Consolim-Colombo FM, Nisenbaum MG, Moraes TL, Giribela AH,
Baracat EC, Melo NR. Effects of a combined oral contraceptive containing 20 mcg
of ethinylestradiol and 3 mg of drospirenone on the blood pressure,
renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile
of healthy young women. Gynecol Endocrinol. 2015 Nov;31(11):912-5. doi:
10.3109/09513590.2015.1062860. Epub 2015 Jul 14. PubMed PMID: 26172927.
8: Jourabchi N, Rhee SM, Lazarus GS. Pre-menstrual flares of pyoderma gangrenosum
controlled with use of a combined oral contraceptive and antiandrogen (Ethinyl
Estradiol/Drospirenone). Br J Dermatol. 2015 Nov 30. doi: 10.1111/bjd.14332.
[Epub ahead of print] PubMed PMID: 26616160.
9: Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results
from a multicenter noncomparative trial of efficacy, safety and tolerability.
Contraception. 2015 Nov;92(5):439-44. doi: 10.1016/j.contraception.2015.07.014.
Epub 2015 Jul 29. PubMed PMID: 26232513.
10: Fan X, Chen X, Wang C, Dai J, Lu Y, Wang K, Liu J, Zhang J, Wu X.
Drospirenone enhances GPIb-IX-V-mediated platelet activation. J Thromb Haemost.
2015 Oct;13(10):1918-24. doi: 10.1111/jth.13109. Epub 2015 Sep 14. PubMed PMID:
26264726.
11: Takeda T, Kondo A, Koga S, Hayakawa J, Hayakawa K, Hiramatsu K, Yaegashi N.
Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in
Japanese patients with dysmenorrhea: Open-label pilot study. J Obstet Gynaecol
Res. 2015 Oct;41(10):1584-90. doi: 10.1111/jog.12774. Epub 2015 Aug 26. PubMed
PMID: 26310836.
12: Santhamma B, Acosta K, Chavez-Riveros A, Nickisch K. A new approach towards
the synthesis of drospirenone and steroidal spirolactones. Steroids. 2015
Oct;102:60-4. doi: 10.1016/j.steroids.2015.07.008. Epub 2015 Jul 26. PubMed PMID:
26216206.
13: Kim N, Yoo HN, Hyun HS, Lee DY, Yoon BK, Choi DS. Efficacy and safety of a
24-day regimen of drospirenone-containing combined oral contraceptive in Korean
women. Obstet Gynecol Sci. 2015 Sep;58(5):397-400. doi:
10.5468/ogs.2015.58.5.397. Epub 2015 Sep 22. PubMed PMID: 26430665; PubMed
Central PMCID: PMC4588845.
14: Al-Jefout M, Nawaiseh N. Continuous Norethisterone Acetate versus Cyclical
Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary
Dysmenorrhea in Young Adult Women. J Pediatr Adolesc Gynecol. 2015 Sep 3. pii:
S1083-3188(15)00310-1. doi: 10.1016/j.jpag.2015.08.009. [Epub ahead of print]
PubMed PMID: 26342733.
15: Sun X, Wu X, Zhou Y, Yu X, Zhang W. Evaluation of Apelin and Insulin
Resistance in Patients with PCOS and Therapeutic Effect of
Drospirenone-Ethinylestradiol Plus Metformin. Med Sci Monit. 2015 Aug
28;21:2547-52. doi: 10.12659/MSM.894926. PubMed PMID: 26314870; PubMed Central
PMCID: PMC4556163.
16: Taniguchi F, Enatsu A, Ota I, Toda T, Arata K, Harada T. Effects of low dose
oral contraceptive pill containing drospirenone/ethinylestradiol in patients with
endometrioma. Eur J Obstet Gynecol Reprod Biol. 2015 Aug;191:116-20. doi:
10.1016/j.ejogrb.2015.06.006. Epub 2015 Jun 16. PubMed PMID: 26115056.
17: Zhao Y, Castiglioni S, Fent K. Environmental Progestins Progesterone and
Drospirenone Alter the Circadian Rhythm Network in Zebrafish (Danio rerio).
Environ Sci Technol. 2015 Aug 18;49(16):10155-64. doi: 10.1021/acs.est.5b02226.
Epub 2015 Jul 28. PubMed PMID: 26161812.
18: Miyashita M, Koga K, Izumi G, Makabe T, Hasegawa A, Hirota Y, Hirata T,
Harada M, Fujii T, Osuga Y. Drospirenone induces decidualization in human eutopic
endometrial stromal cells and reduces DNA synthesis of human endometriotic
stromal cells. Fertil Steril. 2015 Jul;104(1):217-24.e2. doi:
10.1016/j.fertnstert.2015.03.023. Epub 2015 Apr 29. PubMed PMID: 25935489.
19: Cheng J, Zhang Z. [Clinical and metabolic effects of drospirenone-estradiol
versus tibolone in postmenopausal women:a comparative study]. Zhonghua Yi Xue Za
Zhi. 2015 Jun 16;95(23):1815-8. Chinese. PubMed PMID: 26712397.
20: Paoletti AM, Cagnacci A, Di Carlo C, Orrù MM, Neri M, D'Alterio MN, Melis GB.
Clinical effect of hormonal replacement therapy with estradiol associated with
noretisterone or drospirenone. A prospective randomized placebo controlled study.
Gynecol Endocrinol. 2015 May;31(5):384-7. doi: 10.3109/09513590.2014.1003294.
Epub 2015 Feb 23. PubMed PMID: 25703254.
